Delcath Systems Inc. (NASDAQ: DCTH)
$7.96
-0.0050 ( -0.06% ) 156.4K
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Market Data
Open
$7.96
Previous close
$7.96
Volume
156.4K
Market cap
$221.45M
Day range
$7.92 - $8.06
52 week range
$2.25 - $9.18
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Nov 21, 2023 |
4 | Insider transactions | 1 | Nov 21, 2023 |
4 | Insider transactions | 1 | Nov 20, 2023 |
4 | Insider transactions | 1 | Nov 20, 2023 |
10-q | Quarterly Reports | 88 | Nov 13, 2023 |
8-k | 8K-related | 13 | Nov 13, 2023 |
4 | Insider transactions | 1 | Oct 17, 2023 |
8-k | 8K-related | 55 | Sep 06, 2023 |
4 | Insider transactions | 1 | Aug 23, 2023 |
4 | Insider transactions | 1 | Aug 22, 2023 |